Vivus (NASDAQ: [[ticker:VVUS]]), the Mountain View, CA-based developer of an obesity drug, said today it has sold its marketed treatment for erectile dysfunction. Lakewood, NJ-based Meda agreed to pay $23.5 million for the assets related to transurethral alprostadil (Muse). Meda has been business partners with Vivus in Europe since 2000, Vivus said. Selling the Muse assets will allow Vivus to focus on commercializing the obesity drug (Qnexa) that it is seeking to market in the U.S.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
